Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

By Tung N.   Berkowitz R.   Matulonis U.   Quartulli M.   Seiden M.   Kim Y.   Niloff J.   Cannistra S.A.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite

First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: A Phase I Study

By Sehouli J.   Stengel D.   Elling D.   Ortmann O.   Blohmer J.   Riess H.   Lichtenegger W.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 321-326

Academic Press

Access to resources Recommend Favorite

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 673-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up

By Fujiwara K.   Sakuragi N.   Suzuki S.   Yoshida N.   Maehata K.   Nishiya M.   Koshida T.   Sawai H.   Aotani E.   Kohno I.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 637-643

Elsevier

Access to resources Recommend Favorite